Filing Details

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

(Amendment No.    )*

 

Eyenovia, Inc.

(Name of Issuer)

 

Common Stock, $0.0001 par value

(Title of Class of Securities)

 

30234E 104

(CUSIP Number)

 

Shuhei Yoshida

501 Fifth Avenue, Suite 1404

New York, NY 10017

917-289-1117

(Name, Address and Telephone Number of Person Authorized to

Receive Notices and Communications)

 

January 29, 2018

(Date of Event which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☐

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See section 240.13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or other subject to the liabilities of that section of Act but shall be subject to all other provisions of the Act (however, see the Notes).  

  

(Page 1 of 7 Pages)

 

 

Page 2 of 7 Pages

 

CUSIP No. 30234E 104

 

1	Names of Reporting Persons.   Shuhei Yoshida
2	Check the Appropriate Box if a Member of a Group (a)  ¨ (b)  ¨
3	SEC Use Only
4	Source of Funds (See Instructions)   PF
5	Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ¨
6	Citizenship or Place of Organization
	Japan
Number of  Shares Beneficially Owned by  Each  Reporting  Person With		7	Sole Voting Power   25,002 (1)
		8	Shared Voting Power   1,718,566 (2)
		9	Sole Dispositive Power   25,002 (1)
		10	Shared Dispositive Power   1,718,566 (2)
11	Aggregate Amount Beneficially Owned by Each Reporting Person   1,743,568 (1)(2)
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares x
13	Percent of Class Represented by Amount in Row (11)   15.1%
14	Type of Reporting Person   IN

 

	(1)	Includes 25,002 shares of common stock underlying options held by Shuhei Yoshida directly that are exercisable within 60 days of the date of this report.
	(2)	Includes 1,718,566 shares of common stock held by Senju Pharmaceuticals Co., Ltd. Senju Pharmaceuticals Co., Ltd. is owned by the family of Shuhei Yoshida and, therefore, he may be deemed to have beneficial ownership of the shares of common stock held by Senju Pharmaceuticals Co., Ltd.

 

 

Page 3 of 7 Pages

 

CUSIP No. 30234E 104

 

1	Names of Reporting Persons.   Senju Pharmaceuticals Co., Ltd.
2	Check the Appropriate Box if a Member of a Group (a)  ¨ (b)  ¨
3	SEC Use Only
4	Source of Funds (See Instructions)   WC
5	Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ¨
6	Citizenship or Place of Organization
	United States
Number of  Shares Beneficially Owned by  Each  Reporting  Person With		7	Sole Voting Power   1,718,566
		8	Shared Voting Power   0
		9	Sole Dispositive Power   1,718,566
		10	Shared Dispositive Power   0
11	Aggregate Amount Beneficially Owned by Each Reporting Person   1,718,566
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares ¨
13	Percent of Class Represented by Amount in Row (11)   14.9%
14	Type of Reporting Person   OO

 

 

Page 4 of 7 Pages

 

SCHEDULE 13D

 

This Schedule 13D is filed on behalf of Shuhei Yoshida and Senju Pharmaceuticals Co., Ltd., a Japanese company (“Senju” and collectively with Shuhei Yoshida, the “Reporting Persons”).

 

Item 1.

Security and Issuer

 

Securities acquired: common stock, $0.0001 par value per share (“Common Stock”)

 

Issuer:    Eyenovia, Inc. (“Issuer”)

501 Fifth Avenue, Suite 1404

New York, NY 10017

 

Item 2.

Identity and Background

 

(a)

This statement is filed by

 

(i)

Shuhei Yoshida, a member of the Issuer’s Board of Directors (“Board”); and

(ii)

Senju, which is the holder of approximately 14.9% of the issued and outstanding shares of Common Stock as of February 8, 2018.

  

Senju is owned by the family of Shuhei Yoshida and, therefore, he may be deemed to have beneficial ownership of the shares of common stock held by Senju.

 

All disclosures herein with respect to any Reporting Person are made only by such Reporting Person. Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

 

(b) The business address of each of the Reporting Persons is 501 Fifth Avenue, Suite 1404, New York, NY 10017.

 

 (c) Shuhei Yoshida’s principal occupation is to serve as executive vice president and head of Corporate Strategic Planning at Senju. Senju is an ophthalmology pharmaceutical company.

 

(d) None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

 

(e) None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was, or is subject to, a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.

 

(f) Shuhei Yoshida is a Japanese citizen. Senju is a Japanese company.

 

Item 3.

Source and Amount of Funds or Other Consideration.

 

On January 29, 2018, 1,333,333 shares of Common Stock were issued to Senju upon automatic conversion of the Issuer’s Series A preferred stock at the time of the Issuer’s initial public offering (“IPO”). Such shares of Series A preferred stock were purchased with Senju’s working capital on April 1, 2015 at a purchase price of $3.75 per share.

 

On January 29, 2018, 285,233 shares of Common Stock were issued to Senju upon automatic conversion of the Issuer’s Series B preferred stock at the time of the Issuer’s IPO. Such shares of Series B preferred stock were purchased with Senju’s working capital on July 31, 2017 at a purchase price of $6.98 per share.

 

On January 29, 2018, Senju purchased 100,000 shares of Common Stock in the IPO at a purchase price of $10.00 per share.

 

 

Page 5 of 7 Pages

 

Senju is owned by the family of Shuhei Yoshida and, therefore, he may be deemed to have beneficial ownership of the shares of Common Stock held by Senju.

 

25,002 shares of Common Stock underlying options that are exercisable within 60 days of the date of this report were issued to Shuhei Yoshida as compensation for his services to the Issuer.

  

Item 4.

Purpose of the Transaction

  

The shares of Common Stock owned by the Reporting Persons have been acquired for investment purposes. The Reporting Persons may make further acquisitions of the Common Stock from time to time and, subject to certain restrictions, may dispose of any or all of the Common Stock held by the Reporting Persons at any time depending on an ongoing evaluation of the investment in such securities, prevailing market conditions, other investment opportunities and other factors. However, certain of such shares are subject to certain lock-up restrictions as further described in Item 6 below.

 

Except for the foregoing, the Reporting Persons have no plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (c) and (e) through (j) of Item 4 of Schedule 13D.

 

With respect to paragraph (d) of Item 4, the Issuer’s Board is in the process of appointing two additional members to fill the vacancies of the Board in order to comply with the corporate governance requirements of The Nasdaq Stock Market and Shuhei Yoshida currently serves as a member of the Board.

 

Item 5.          Interest in Securities of the Issuer

 

(a)-(b) The aggregate number and percentage of Common Stock beneficially owned by the Reporting Persons (on the basis of a total of 9,936,771 shares of Common Stock outstanding as of February 8, 2018) are as follows: 

 

Shuhei Yoshida

a)		Amount beneficially owned: 1,743,568		Percentage: 15.1%
b)		Number of shares to which the Reporting Person has:
	i.	Sole power to vote or to direct the vote:		25,002 (1)
	ii.	Shared power to vote or to direct the vote:		1,718,566 (2)
	iii.	Sole power to dispose or to direct the disposition of:		25,002 (1)
	iv.	Shared power to dispose or to direct the disposition of:		1,718,566 (2)

 

	(1)	Includes 25,002 shares of Common Stock underlying options held by Shuhei Yoshida directly that are exercisable within 60 days of the date of this report.
	(2)	Includes 1,718,566 shares of Common Stock held by Senju Pharmaceuticals Co., Ltd. Senju Pharmaceuticals Co., Ltd. is owned by the family of Shuhei Yoshida and, therefore, he may be deemed to have beneficial ownership of the shares of Common Stock held by Senju Pharmaceuticals Co., Ltd.

 

Senju Pharmaceuticals Co., Ltd.

a)		Amount beneficially owned: 1,718,566		Percentage: 14.9%
b)		Number of shares to which the Reporting Person has:
	i.	Sole power to vote or to direct the vote:		1,718,566
	ii.	Shared power to vote or to direct the vote:		0
	iii.	Sole power to dispose or to direct the disposition of:		1,718,566
	iv.	Shared power to dispose or to direct the disposition of:		0

 

(c) On January 29, 2018, 1,333,333 shares of Common Stock were issued to Senju upon automatic conversion of the Issuer’s Series A preferred stock at the time of the Issuer’s IPO.

 

On January 29, 2018, 285,233 shares of Common Stock were issued to Senju upon automatic conversion of the Issuer’s Series B preferred stock at the time of the Issuer’s IPO.

 

 

Page 6 of 7 Pages

 

On January 29, 2018, Senju purchased 100,000 shares of Common Stock in the IPO at a purchase price of $10.00 per share.

 

Except as described herein, the Reporting Person has not effected any transactions of the Issuer’s Common Stock during the 60 days preceding the date of this report.

 

(d) Not applicable.

 

(e) Not applicable.

 

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

  

On January 4, 2018, in connection with the Issuer’s IPO, Shuhei Yoshida entered into a lock-up agreement with the underwriters of the IPO, pursuant to which he agreed that for a period of 180 days after January 24, 2018, or the lock-up period, subject to certain limited exceptions described below, he will not directly or indirectly, without the prior written consent of the underwriters offer for sale, contract to sell, sell, distribute, grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly or indirectly, any shares of the Common Stock (excluding shares purchased in the IPO) or any securities convertible into, or exercisable or exchangeable for, shares of the Common Stock. Certain limited transfers are permitted during the lock-up period if the transferee agrees to these lock-up restrictions.

 

The description of the lock-up agreement is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed as Exhibit 10.1 to this report and are incorporated by reference herein.  

  

Item 7.

Material to be Filed as Exhibits

 

Exhibit 10.1		Lock-Up Agreement between Shuhei Yoshida and the underwriters dated January 4, 2018
Exhibit 99.1		Joint Filing Agreement by and among the Reporting Persons

 

  

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 14, 2018		/s/ Shuhei Yoshida
		Shuhei Yoshida

 

Date: February 14, 2018	Senju Pharmaceuticals Co., Ltd.
	By:	/s/ Shuhei Yoshida
		Name: Shuhei Yoshida
		Title: Executive Vice President